Nima Mesbah Ardakani

Nima Mesbah Ardakani

Auto-generated profile, based on publicly available information

Nima Mesbah Ardakani

Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2017 in Pathology
Verified
Journal Article
Closed access
PDF file
NANima Mesbah Ardakani
Nima Mesbah Ardakani
CTCarla Thomas
Carla Thomas
CRCleo Robinson
Cleo Robinson
KMKym Mina
Kym Mina
NHNathan Tobias Harvey
Nathan Tobias Harvey
BWBenjamin Andrew Wood
Benjamin Andrew Wood

1 September 2021 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
WLWeitao Lin
Weitao Lin
ABAaron Beasley
Aaron Beasley
NANima Mesbah Ardakani
Nima Mesbah Ardakani
EDElena Denisenko
Elena Denisenko
LCLeslie Calapre
Leslie Calapre
Elin GrayElin Gray
Elin Gray
Tumor heterogeneity is a major obstacle to the success of cancer treatment. An accurate understanding and recognition of tumor heterogeneity is critical in the clinical management of cancer patients. Here, we utilized single-cell RNA sequencing (scRNA-seq) to uncover the intra- and intertumoral heterogeneity of liver metastases from a patient with metastatic uveal melanoma. The two metastases analyzed were largely infiltrated by noncancerous cells with significant variability in the proportion of different cell types. Analysis of copy-number variations (CNVs) showed gain of 8q and loss of 6q in both tumors, but loss of Chromosome 3 was only detected in one of the tumors. Single-nucleotide polymorphism (SNP) array revealed a uniparental isodisomy 3 in the tumor with two copies of Chromosome 3, indicating a regain of Chromosome 3 during the development of the metastatic disease. In addition, both tumors harbored subclones with additional CNVs. Pathway enrichment analysis of differentially expressed genes revealed that cancer cells in the metastasis with isodisomy 3 showed up-regulation in epithelial–mesenchymal transition and myogenesis related genes. In contrast, up-regulation in interferon signaling was observed in the metastasis with monosomy 3 and increased T-cell infiltrate. This study highlights the complexity and heterogeneity of different metastases within an individual case of uveal melanoma.

1 June 2019 in Pathology
Verified
Journal Article
Closed access
DCDaniel Ching
Daniel Ching
EAElham Amini
Elham Amini
NHNathan Tobias Harvey
Nathan Tobias Harvey
BWBenjamin Andrew Wood
Benjamin Andrew Wood
NANima Mesbah Ardakani
Nima Mesbah Ardakani

7 March 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
NANima Mesbah Ardakani
Nima Mesbah Ardakani
CLConnull Leslie
Connull Leslie
FGFabienne Grieu‐Iacopetta
Fabienne Grieu‐Iacopetta
WLWei‐Sen Lam
Wei‐Sen Lam
CBCharley Budgeon
Charley Budgeon
BABenhur Amanuel
Benhur Amanuel

16 September 2023 in Pathology
Verified
Journal Article
Closed access
SHShona Hendry
Shona Hendry
LMLouis Mamotte
Louis Mamotte
NANima Mesbah Ardakani
Nima Mesbah Ardakani
CLConnull Leslie
Connull Leslie
YTYordanos Tesfai
Yordanos Tesfai
BABenhur Amanuel
Benhur Amanuel

7 July 2020 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
NANima Md Mesbah Ardakani
Nima Md Mesbah Ardakani
SSShalinder Msc Singh
Shalinder Msc Singh
CTCarla Thomas
Carla Thomas
CVChris Frcpa Van Vliet
Chris Frcpa Van Vliet
NHNathan Tobias Frcpa Harvey
Nathan Tobias Frcpa Harvey
BWBenjamin Andrew Frcpa Wood
Benjamin Andrew Frcpa Wood
The distinction between nevoid melanoma and a mitotically active nevus can be challenging at the microscopic level. In this study, we performed cytogenetic testing on a cohort of 25 mitotically active melanocytic proliferations resembling common melanocytic nevus from 25 patients. Based on cytogenetic findings, the lesions were classified as “nevoid melanoma” (n = 13) or “mitotically active nevus” (n = 12). Subsequently, we compared the clinicopathological features between these 2 groups. Nevoid melanomas occurred in older patients (P = 0.007); however, there were no significant differences in gender, size, or anatomical distribution between the 2 groups. Histologically, deep/marginal mitoses (P = 0.006), lack of maturation with depth (P = 0.036), and pseudo-maturation (P = 0.006) were significantly more common in nevoid melanomas. Immunohistochemically, complete loss of p16 was an important divisive feature (P = 0.0004), seen in 70% of nevoid melanomas, and highly correlated with loss of CDKN2A gene (chromosome 9p21). Our findings suggest that such reproducible immunomorphological differences can be of value in distinguishing nevoid melanoma from mitotically active nevus. Nevoid melanomas demonstrated a spectrum of chromosomal aberrations similar to those seen in common subtypes of melanoma, which can serve as a powerful adjunct diagnostic tool in morphologically challenging lesions.